Abstract
Advances in pharmacogenomics have improved understanding of allopurinol hypersensitivity syndrome (AHS), and new research suggests HLA-B*5801 is a strong risk factor for this condition; in some populations, almost all patients who develop AHS carry this allele. This discovery could influence the treatment of gout, in particular, how allopurinol is used.
Publication types
-
News
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Allopurinol / adverse effects*
-
Allopurinol / therapeutic use
-
Arthritis, Gouty / drug therapy
-
Arthritis, Gouty / genetics*
-
Drug Eruptions / etiology
-
Drug Eruptions / genetics*
-
Female
-
Forecasting
-
Gene Expression Regulation
-
Genotype
-
HLA-B Antigens / genetics*
-
HLA-B Antigens / metabolism
-
Humans
-
Male
-
Molecular Targeted Therapy / methods
-
Molecular Targeted Therapy / trends
-
Pharmacogenetics
-
Risk Assessment
-
Treatment Outcome
Substances
-
HLA-B Antigens
-
Allopurinol